The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
about
Follicular lymphoma: 2012 update on diagnosis and managementBortezomib for the treatment of mantle cell lymphoma: an updateThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient managementThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyMantle cell lymphoma: observation to transplantationEsters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma CellsNeovascular niche for human myeloma cells in immunodeficient mouse boneA retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphomaBortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas.Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysisRetrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancyOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaThe expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphomaUpdate on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibProteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideBortezomib in mantle cell lymphoma: comparative therapeutic outcomesA novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells.Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Management of indolent lymphoma: where are we now and where are we going.Non-Hodgkin's lymphomas, version 4.2014.Bortezomib for the treatment of non-Hodgkin's lymphomaTargeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Idelalisib for the treatment of non-Hodgkin lymphoma.The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.
P2860
Q22252956-FF498377-BB38-4205-A413-0DC703AB4242Q26738940-2B97386A-A9AE-44C2-A3CE-172381EF3735Q26772907-C44A5D2C-0007-481B-BC3A-2897177DBC33Q27002428-A8AB1A54-2D4B-4634-8484-85FC71F8F514Q28072397-3B61B58D-3F45-4E8D-8A74-389E6389C61CQ28075606-8EB66378-8BB8-45A9-AD09-E7340284ECF4Q28080304-1777D5AE-6FE4-406B-9BEA-6F69729427D7Q28256317-53922AF3-4853-49A8-9FDB-89CBAAD64966Q28552720-E3F00ADB-05B5-4BD0-98BF-2F213382B632Q28732210-A2F0D678-564F-4F2C-A266-F1C6368B1E77Q33398818-8FC60A0F-F5C3-4DF1-BAE9-F32656B521D1Q33402885-E73AC28B-FB2E-4EA9-B533-52C332C8EB09Q33404350-3B3E9C5F-9687-4978-9E7F-D177B39ACF37Q33410756-8206667C-5277-4B6F-B0A2-13155155140BQ33416533-9C49AA33-DB11-421F-94BB-9A7BC9C3C5E1Q33417803-E7639075-D3C4-4684-B43C-B4E534C930F2Q33419346-A0C08E3A-6777-4FCA-8E80-7A58ABEF541EQ33421147-0590962E-E9DA-4CDB-BB79-17EACAD4BA9AQ33586239-8AA7BA7E-FF9B-4F83-9A68-1D9802EF06D8Q33713106-60EC379F-D79B-4116-B21E-3B967D2B6883Q33877999-83D305B2-E4F5-4382-9E75-EC900B235582Q34322781-4CE9B7CC-71AC-40D6-8FF5-77C4C88F6F8BQ34788381-92A012C4-1B33-45F3-8269-CDC2181F53CEQ35052538-FABD212A-E2ED-4BE6-9B56-600D6A47C231Q35475256-9F4AA4AE-FAB7-461E-ABE5-9F1CA56E0D76Q35905929-949B49F7-5275-4270-BD43-EC75AB914795Q35989980-184F21F6-E0BE-4F67-8E34-A0FF67789855Q36278006-CB80A96A-B1F5-4AFE-822C-6EC700288282Q36299600-EEF67F21-A358-4EFC-9C7D-546F39B9667FQ36456078-324CA2C2-EF03-498A-8ED0-DABCAEF882B8Q36784860-BC0CE4A0-86EF-4DAD-9CFD-AB80289D8F34Q36820885-83BAE7C1-B770-448B-8F05-997F03776D30Q36868056-5C9AA69C-F682-43CD-9EE5-6B2A705B69B4Q36889248-EDBF826C-E0FA-454E-8C8C-E022BE3E89D9Q37057176-CD7C2AE0-051C-4DA6-9942-46E6E70758DDQ37065959-5DC58183-8FC7-4D6A-AFE2-D451228FD552Q37114445-70FEF087-FF95-44DB-8F0B-E3B871B7D5C3Q37132187-BD93397B-EADE-4C4B-B6CC-4EB3A4DE45B3Q37178611-EE1DBB71-E4AF-4738-836A-D49F298801D7Q37524930-FCB2035E-4F56-4B20-86A3-A5E33D74C5D0
P2860
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@ast
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@en
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@nl
type
label
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@ast
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@en
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@nl
prefLabel
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@ast
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@en
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@nl
P2093
P2860
P1433
P1476
The combination of bendamustin ...... ntle cell non-Hodgkin lymphoma
@en
P2093
Derick Peterson
Faith Young
Jane Liesveld
Jennifer L Kelly
John P Leonard
Jonathan W Friedberg
Nicole K Proia
Richard I Fisher
Steven Grant
P2860
P304
P356
10.1182/BLOOD-2010-11-314708
P407
P577
2011-01-14T00:00:00Z